EACVI Premium Access

Poster session 1 - Imaging: Myocardial Disease

Event: EuroEcho 2019

Topic: Cross-Modality and Multi-Modality Imaging Topics, Other

Session type: Poster Session

Date: 4 December 2019

Time: 09:00 - 16:00

Session

6 presentations in this session

Antimalarial-induced cardiomyopathy: retrospective case series

Speaker: Doctor N. Pavsic (Ljubljana, SI)

Thumbnail

Cardiac magnetic resonance characteristics of patients in the grey zone of hypertrophy

Speaker: Doctor C. Czimbalmos (Budapest, HU)

Thumbnail

The first prospective study of non-compaction cardiomyopathy patients with preserved ejection fraction using cardiac magnetic resonance feature tracking

Speaker: Doctor A. Kiss (Budapest, HU)

Thumbnail

Echocardiographic deformation imaging improves detection of arrhythmogenic right ventricular cardiomyopathy; a head-to-head comparison of deformation imaging and conventional assessment

Speaker: Mr F. Kirkels (Utrecht, NL)

Thumbnail

Role of mechanical dispersion in the prediction of heart failure admissions in dilated non ischemic cardiomyopathy

Speaker: Doctor M. Ferrandez (Madrid, ES)

Thumbnail

Cardioprotective effect of angiotensin converting enzyme inhibitors and beta-blockers in the primary prevention of cardiotoxicity: systematic review and meta-analysis of randomised studies

Speaker: Doctor S. Moral (Girona, ES)

Thumbnail

6 speakers from this session

Doctor Nejc Pavsic

University Medical Centre of Ljubljana, Ljubljana (Slovenia)

0 follower

Doctor Csilla Czimbalmos

Semmelweis University Heart and Vascular Center, Budapest (Hungary)

1 presentation

0 follower

Doctor Anna Reka Kiss

Semmelweis University, Budapest (Hungary)

1 presentation

0 follower

Mr Feddo Kirkels

University Medical Center Utrecht, Utrecht (Netherlands (The))

0 follower

Doctor Marcos Ferrandez

San Carlos Clinical University Hospital, Madrid (Spain)

0 follower

Doctor Sergio Moral

University Hospital de Girona Dr. Josep Trueta, Girona (Spain)

0 follower

This platform is supported by

logo Novo Nordisk